Yinchuan Shanghetu New Technology R&D Co., Ltd., established on 2013-10-28, Business scope includes research and development of practical new technologies;Research and development of high-tech popularization methods;Research and development of new educational methods;Health products,Food and its quality preservation technology,Research and Development of Fresh Fruit and Vegetable Preservation Technology;Food and dried and fresh fruit packaging sales;Production and sales of plastic packaging containers.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Novomics develops cancer treatment-linked diagnosis systems based on its expertise and knowledge in the field of molecular diagnosis. A significant strength of Novomics is its network of specialists and clinicians, as well as the knowledge gains made possible by technological advancements in the age of precision medicine. By embracing cutting-edge clinical, molecular biological, and academic achievements and forming close collaborative relationships with pharmaceutical companies and hospitals that are significant players in the medical industry.

Beijing Kawin Technology Share-Holding Co., Ltd. (Kawin Technology) is located in the Beijing Economy-Technology Development Area (BDA), also well known as the "Pharmaceutical Valley". Based on biotechnology platforms, Kawin Technology is committed to become a public company that provides the best healthcare solutions to liver disease for our patients. Since establishment, Kawin Technology has formed strategic partnership with Legend Capital, Haitong Capital and Cybernaut respectively. Kawin Technology is a High & New Technology Enterprise certified by Beijing Municipal Science & Technology Commission. It has also been listed as one of Hundred Pilot Enterprises and Top 100 Most-promising Enterprises by Zhongguancun Technology Park (also know as China’s Silicon Valley).

Shandong Kaige Intelligent Machine Co., Ltd., established on 2016-08-26, The scope of business includes machinery and equipment,medical instruments,Development of daily disinfection products,Sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Carti (Shanghai) Cell Biotechnology Co., Ltd., established on 2016-03-31, Business scope includes biotechnology,Cell Medicine Technology,Medical Device Technology,Technology development in the field of laboratory equipment technology,Technical Services,technical consulting,technology transfer,Business Management Consulting,Health Management Consulting. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

National Cancer Center Korea is a South Korean company located in Goyang-si and ultimately controlled by the Government of South Korea. The firm provides clinical and medical research services.

A leader in therapeutic antibodies, ImClone Systems (also called "the company") is committed to advancing oncology care by developing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. Founded in 1984, ImClone has a rich culture of discovery and deep expertise in oncology. The company has utilized the many advances made in the fields of molecular biology, oncology, genomics, and antibody engineering to build a novel pipeline of product candidates designed to address specific genetic mechanisms involved in cancer growth and development. Beyond its blockbuster marketed product ERBITUX®, ImClone has several additional investigational monoclonal antibodies in various stages of clinical development. Following its acquisition by Eli Lilly and Company in 2008, ImClone Systems is accelerating its antibody pipeline development by leveraging Lilly's global capabilities. ImClone's pipeline has several molecules in mid- to late-stage clinical development targeting virtually all major solid tumor types. Additionally, ImClone plans to advance several additional targets from its research programs into clinical development over the coming years. ImClone's research and clinical development capabilities are augmented by its expertise in the scale-up and manufacturing of biologics. The company's state-of-the-art FDA-approved manufacturing facilities in Branchburg, New Jersey, provide it with one of the largest biologic manufacturing capacities in the world. ImClone's Branchburg campus also houses it clinical development and administration operations. The company's research headquarters are based in New York City and it has international operations in Europe.

Seoul National University Hospital (서울대학교병원) is one of the oldest and biggest hospitals in South Korea. It is a general and teaching hospital of Seoul National University's College of Medicine. Except SNUH Healthcare System Gangnam Center, all branches have an emergency department (ED).

Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ.

Zhongshan Baiou Pharmaceutical Technology Co., Ltd., established on 2014-07-14, Business scope includes pharmaceutical biotechnology,medical instruments,Research and development of cosmetics and related technical consultation,Technology transfer service.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments.)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)